CN101537011B - 预防或治疗帕金森病的药物组合物及其制备方法 - Google Patents
预防或治疗帕金森病的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN101537011B CN101537011B CN200910135572XA CN200910135572A CN101537011B CN 101537011 B CN101537011 B CN 101537011B CN 200910135572X A CN200910135572X A CN 200910135572XA CN 200910135572 A CN200910135572 A CN 200910135572A CN 101537011 B CN101537011 B CN 101537011B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- radix
- acanthopanacis senticosi
- caulis acanthopanacis
- glucoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 208000027089 Parkinsonian disease Diseases 0.000 title abstract 3
- 206010034010 Parkinsonism Diseases 0.000 title abstract 3
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 claims abstract description 21
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 claims abstract description 20
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 229930182478 glucoside Natural products 0.000 claims description 59
- 150000008131 glucosides Chemical class 0.000 claims description 59
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 claims description 18
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 claims description 18
- 239000003085 diluting agent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 35
- 230000004083 survival effect Effects 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 238000003908 quality control method Methods 0.000 abstract description 3
- 230000001681 protective effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- FFDULTAFAQRACT-OVUSVGQASA-N Eleutheroside D Chemical compound COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-OVUSVGQASA-N 0.000 abstract 4
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 abstract 2
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000005064 dopaminergic neuron Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000005779 cell damage Effects 0.000 description 13
- 208000037887 cell injury Diseases 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 8
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000012109 statistical procedure Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- -1 1-methyl-4 phenylpyridine ion Chemical class 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 125000004395 glucoside group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910135572XA CN101537011B (zh) | 2009-04-27 | 2009-04-27 | 预防或治疗帕金森病的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910135572XA CN101537011B (zh) | 2009-04-27 | 2009-04-27 | 预防或治疗帕金森病的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101537011A CN101537011A (zh) | 2009-09-23 |
CN101537011B true CN101537011B (zh) | 2011-06-01 |
Family
ID=41120552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910135572XA Expired - Fee Related CN101537011B (zh) | 2009-04-27 | 2009-04-27 | 预防或治疗帕金森病的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101537011B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102755343A (zh) * | 2012-08-08 | 2012-10-31 | 南京中医药大学 | 胡萝卜苷在制备促进神经干细胞增殖药物中的应用 |
CN109223816B (zh) * | 2018-11-20 | 2021-10-26 | 江苏省中国科学院植物研究所 | 刺五加苷d在制备抗抑郁症药物中的应用 |
KR102280202B1 (ko) * | 2021-02-26 | 2021-07-22 | 옙바이오 주식회사 | 엘레우테로사이드 b를 유효성분으로 포함하는 뇌신경염증 치료용 약학적 조성물 |
CN113209114B (zh) * | 2021-05-18 | 2022-04-19 | 华中农业大学 | PGC-1α激活剂胡萝卜苷在制备防治血脑屏障损伤药物中的应用 |
-
2009
- 2009-04-27 CN CN200910135572XA patent/CN101537011B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101537011A (zh) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102225152B (zh) | 麦味地黄口服制剂的制备方法 | |
CN103182049B (zh) | 一种治疗中风后遗症的药物组合物制剂的制备方法 | |
CN1704085A (zh) | 一种具有免疫调节作用的药物组合物及其制备方法 | |
CN101537011B (zh) | 预防或治疗帕金森病的药物组合物及其制备方法 | |
CN103169737B (zh) | 樟芝子实体与破壁灵芝孢子粉的组合物及其在免疫调节中的应用 | |
CN102716223B (zh) | 一种治疗上呼吸道感染的中药组合物及其制备方法 | |
CN101850032B (zh) | 一种具有抗肿瘤作用的中药组合物及其制备方法和应用 | |
CN112675255B (zh) | 用于预防治疗受试者抑郁症的药物组合物及用途 | |
CN1775267A (zh) | 一种开口箭提取物及其制备方法和应用 | |
CN104069194B (zh) | 一种具有抗癌作用的中药组合物及其制备方法和用途 | |
CN109288870A (zh) | 僵蚕水提物在制备抗惊厥药物中的应用 | |
CN104367633A (zh) | 一种有抗菌及增效抗菌作用的药物组合及制备方法与应用 | |
CN103690539B (zh) | 钩吻素子及其同系物在制备治疗糖尿病并发症药物中的应用 | |
CN1686424A (zh) | 一种含有黄芩和柴胡的药物组合物及其制备方法 | |
CN102961443B (zh) | 北豆根抗肿瘤提取物、制备方法及用途 | |
CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
CN104706729A (zh) | 一种具有抗肿瘤功效的中药提取物及其提取方法和应用 | |
CN1233358C (zh) | 败酱草中抗呼吸道合胞病毒物质的提取方法 | |
CN107929344B (zh) | 一种用于预防及治疗喉癌的紫草复方组合物 | |
CN108041603A (zh) | 一种具有改善睡眠作用的保健食品及其制备方法和应用 | |
CN109602775B (zh) | 乳苣醇提物在制备抗乳腺癌药物中的用途 | |
CN103191268B (zh) | 一种治疗肺癌的中药组合物 | |
CN104825784B (zh) | 一种具有抗胃癌活性的中药组合物及其制备方法和应用 | |
CN107126474B (zh) | 清开灵组合物在制备治疗和/或预防辐射损伤药物中的应用 | |
CN106831386A (zh) | 新型蕨素类化合物在治疗糖尿病的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191213 Address after: No.16, Tongsheng Road, Limin Development Zone, Harbin City, Heilongjiang Province Patentee after: Harbin HouBo Biomedical Technology Service Co.,Ltd. Address before: 150040, Heping Road, Xiangfang, Heilongjiang, 24, Heilongjiang University Of Chinese Medicine, Harbin, China Patentee before: Liu Shumin |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210729 Address after: 150000 No. 269, Pubei street, Songbei District, Harbin, Heilongjiang Patentee after: HA ERBIN SHENGYUAN BIOENGINEER Address before: 150070 No. 16, Tongsheng Road, Limin Development Zone, Harbin, Heilongjiang Patentee before: Harbin HouBo Biomedical Technology Service Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110601 |